Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iodamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodamide SCHEMBL9808844 | 0.99 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Diatrizoic Acid SCHEMBL1685085 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Diatrizoic Acid SCHEMBL107036 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Diatrizoic Acid SCHEMBL720469 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Diatrizoic Acid SCHEMBL468613 | 0.88 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Diatrizoic Acid SCHEMBL2501947 | 0.88 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Iothalamic Acid SCHEMBL48785 | 0.84 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Iothalamic Acid SCHEMBL180546 | 0.84 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Iothalamic Acid SCHEMBL29488709 | 0.84 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR | |
| Iothalamic Acid SCHEMBL3060866 | 0.83 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAKDM4ECYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | claimed |
| WO-2008113372-A2 | ELECTROACTIVE POLYMER ACTUATOR DEVICES AND SYSTEMS COMPRISING SUCH DEVICES | MICROMUSCLE AB (SE) | 2008-09-25 | — | — | WO | claimed |
| WO-2005030267-A1 | PHARMACEUTICALLY ENHANCED LOW-ENERGY RADIOSURGERY | SIRIUS MEDICINE, LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20040006254-A1 | Pharmaceutically enhanced low-energy radiosurgery | SIRIUS MEDICINE, LLC | 2004-01-08 | — | — | US | claimed |
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025083437-A1 | THE USE OF TP3 (THYMOPENTIN ANALOG) BY INCREASING THE ACTIVITY AND NUMBER OF T-CELLS INVOLVED IN THE DEFENSE MECHANISM OF THE IMMUNE SYSTEM OF MAMMALS, FOR THE PREVENTION OR TREATMENT OF DISEASES TO EXTEND THE AVERAGE LIFESPAN | DENES LASZLO (HU) | 2025-04-24 | — | — | WO | disclosed |
| CN-119548500-A | Agents for treating contrast-induced acute kidney injury | 阿普塔生物治疗公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| EP-3741381-B1 | A PEPTIDE FOR USE FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | UNIV CORNELL (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | CORNELL UNIVERSITY (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230201179-A1 | AGENT FOR TREATING CONTRAST-INDUCED ACUTE KIDNEY INJURY | APTABIO THERAPEUTICS INC. (KR) | 2023-06-29 | — | — | US | disclosed |
| US-11628198-B2 | Methods for prevention and treatment of acute renal injury | CORNELL UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| US-4551132-A | Pharmaceutically acceptable silicon rubber and therapeutical set and the use thereof for surgical embolization | PASZTOR EMIL (HU) | 1985-11-05 | — | — | US | disclosed |
| EP-0132983-A1 | Production of gelatin spherical gels and their use | Hitachi Chemical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
| US-4477255-A | Pharmaceutically acceptable silicon rubber and therapeutical set and the use thereof for surgical embolization | PASZTOR EMIL (HU) | 1984-10-16 | — | — | US | disclosed |
| EP-0034375-B1 | SILICON RUBBER MIXTURE FOR THERAPEUTIC APPLICATION AND AS A HEALING AID | Lazar, Laszlo, Dr. (HU) | 1984-08-22 | — | — | EP | disclosed |
| US-4429062-A | Pharmaceutically acceptable silicon rubber and therapeutical set and the use thereof for surgical embolization | PASZTOR EMIL (HU) | 1984-01-31 | — | — | US | disclosed |
| EP-0034375-A2 | Silicon rubber mixture for therapeutic application and as a healing aid | Lazar, Laszlo, Dr. (HU) | 1981-08-26 | — | — | EP | disclosed |
| US-4285928-A | AN EMULSION OF AN X-RAY CONTRAST AGENT AND A MIXTURE OF PERFLUORO COMPOUNDS HAVING OXYGEN-CARRYING ABILITIES | Wada, Juro (JP) | 1981-08-25 | — | — | US | disclosed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628198-B2 | Methods for prevention and treatment of acute renal injury | ARG2, SERPINC1, ARG1 | SMN1; SMN2 4340/4885LMNA 2196/4885KDM4E 4693/4885 |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | ARG2, SERPINC1, ARG1 | SMN1; SMN2 4340/4885LMNA 2196/4885KDM4E 4693/4885 |
| US-20230201179-A1 | AGENT FOR TREATING CONTRAST-INDUCED ACUTE KIDNEY INJURY | ATP6V1B1, REN, ATF1 | SMN1; SMN2 3235/4885LMNA 1586/4885KDM4E 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.